From Me to We

The Scientist Community is about to take off. We hope you'll join us.

| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

This is my page. Here, I get to talk every month about whatever I want. I like that.

The editorial staff (there's half-a-dozen besides me) decide what's going to be in the magazine each month, and what stories we are going to report on the Web site every day. We like that too.

But things could be a lot - a whole lot - more interesting.

What if, instead of being a passive consumer of The Scientist, our readers played a role in shaping the content? We could have 700, or 7,000, minds thinking up and debating great story ideas, instead of just seven. Such a community could identify breakthrough research and commercialization opportunities before they received widespread attention. Or decide on the fields and firms that are being oversold. It could identify scandals, tag the unrecognized heroes and geniuses of science and business, and work out and test ways ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

  • Richard Gallagher

    This person does not yet have a bio.

Published In

Share
TS Digest January 2025
January 2025, Issue 1

Why Do Some People Get Drunk Faster Than Others?

Genetics and tolerance shake up how alcohol affects each person, creating a unique cocktail of experiences.

View this Issue
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo
New Frontiers in Vaccine Development

New Frontiers in Vaccine Development

Sino
New Approaches for Decoding Cancer at the Single-Cell Level

New Approaches for Decoding Cancer at the Single-Cell Level

Biotium logo
Learn How 3D Cell Cultures Advance Tissue Regeneration

Organoids as a Tool for Tissue Regeneration Research 

Acro 

Products

Artificial Inc. Logo

Artificial Inc. proof-of-concept data demonstrates platform capabilities with NVIDIA’s BioNeMo

Sapient Logo

Sapient Partners with Alamar Biosciences to Extend Targeted Proteomics Services Using NULISA™ Assays for Cytokines, Chemokines, and Inflammatory Mediators

Bio-Rad Logo

Bio-Rad Extends Range of Vericheck ddPCR Empty-Full Capsid Kits to Optimize AAV Vector Characterization

Scientist holding a blood sample tube labeled Mycoplasma test in front of many other tubes containing patient samples

Accelerating Mycoplasma Testing for Targeted Therapy Development